Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis

NCT03089775 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Contact Dermatitis

Interventions

DRUG: BBI-2000
DRUG: Vehicle
OTHER: Multiple treatments

Sponsor

Fresh Tracks Therapeutics, Inc.